AsiaMedic posted FY2025 revenue of SGD 35.2 million, up 22% year on year, as diagnostic imaging and radiology services rose to SGD 23.1 million. FY2025 profit after tax was SGD 1.4 million, up 121%, with profit attributable to owners at SGD 2.0 million (up 100%) and FY2025 EBITDA at SGD 5.6 million. For 2H2025, revenue was SGD 18.6 million (up 18%) and profit after tax was SGD 2.0 million (up 173%). Basic and diluted EPS for FY2025 were 0.18 Singapore cents. The group completed the disposal of its 60% stake in AsiaMedic Astique The Aesthetic Clinic on 31 October 2025 for SGD 0.15 million, retaining a 40% interest accounted for as an associate; it recorded FY2025 gains of SGD 1.7 million from deconsolidation and SGD 0.2 million from disposal, alongside an expected credit loss provision of SGD 1.0 million on a shareholder loan to the associate. Management said FY2025 growth was supported by higher patient volumes and the ramp-up of its diagnostic imaging centre at Royal Square Medical Centre Novena, and noted it expects lower contribution from on-site healthcare services after it was not awarded the subsequent tender for the HPB school health screening project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AsiaMedic Limited published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: RWPRONQ1W45XPTGB) on March 01, 2026, and is solely responsible for the information contained therein.